Literature DB >> 22120844

A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.

Lyn Schofield1, Fabienne Grieu, Jack Goldblatt, Benhur Amanuel, Barry Iacopetta.   

Abstract

We have previously established in a large retrospective study that testing for microsatellite instability (MSI) in colorectal cancer (CRC) from patients aged <60 years was an effective first screen to identify individuals with Lynch syndrome (LS). From these findings, MSI and/or immunohistochemical (IHC) screening was recommended for all newly diagnosed CRC patients aged <60 years in Western Australia, regardless of family history of cancer. In the current study we evaluated the utility of routine MSI/IHC screening by diagnostic pathology laboratories for the detection of previously undiagnosed individuals and families with LS. From January 2009 to December 2010, 270 tumours were tested for MSI and for expression of MLH1, PMS2, MSH2 and MSH6 using IHC. Cases showing MSI and/or loss of expression were also tested for the BRAF V600E hotspot mutation. Seventy cases were found to have MSI, of which 25 were excluded from further investigation as possible LS cases due to presence of the BRAF V600E mutation. The remaining 45 "red flag" cases were eligible for germline testing based on their MSI, IHC and BRAF status. From 31 cases tested to date, 15 germline mutations have been found. Thirteen were from individuals not previously recognized as LS and two were untested members from known LS families. Extrapolation of the mutation incidence (15/31, 48%) to all red flag cases (n = 45) suggests that approximately 22 mutation carriers exist in this cohort. This value approximates the number of CRC cases due to LS that could be expected to arise in the Western Australian population over a two-year period (n = 24), assuming that 1% of all CRCs are due to LS. Although further improvements in workflow can be made, our preliminary findings following the implementation of state-wide routine MSI and IHC testing in Western Australia indicate that the majority of LS cases are being identified.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22120844     DOI: 10.1007/s10689-011-9494-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  26 in total

1.  The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer.

Authors:  W S Samowitz; K Curtin; H H Lin; M A Robertson; D Schaffer; M Nichols; K Gruenthal; M F Leppert; M L Slattery
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

2.  Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.

Authors:  Jinru Shia; David S Klimstra; Khedoudja Nafa; Kenneth Offit; Jose G Guillem; Arnold J Markowitz; William L Gerald; Nathan A Ellis
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

3.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer.

Authors:  R Salovaara; A Loukola; P Kristo; H Kääriäinen; H Ahtola; M Eskelinen; N Härkönen; R Julkunen; E Kangas; S Ojala; J Tulikoura; E Valkamo; H Järvinen; J P Mecklin; L A Aaltonen; A de la Chapelle
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas.

Authors:  J M Cunningham; C Y Kim; E R Christensen; D J Tester; Y Parc; L J Burgart; K C Halling; S K McDonnell; D J Schaid; C Walsh Vockley; V Kubly; H Nelson; V V Michels; S N Thibodeau
Journal:  Am J Hum Genet       Date:  2001-08-24       Impact factor: 11.025

5.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

6.  Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test.

Authors:  Lyn Schofield; Natasha Watson; Fabienne Grieu; Wei Qi Li; Nik Zeps; Jennet Harvey; Colin Stewart; Michael Abdo; Jack Goldblatt; Barry Iacopetta
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

7.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

8.  BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer.

Authors:  Guoren Deng; Ian Bell; Suzanne Crawley; James Gum; Jonathan P Terdiman; Brian A Allen; Brindusa Truta; Marvin H Sleisenger; Young S Kim
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

9.  Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer.

Authors:  Natasha Watson; Fabienne Grieu; Melinda Morris; Jennet Harvey; Colin Stewart; Lyn Schofield; Jack Goldblatt; Barry Iacopetta
Journal:  J Mol Diagn       Date:  2007-07-25       Impact factor: 5.568

10.  BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.

Authors:  Wei Qi Li; Kazuyuki Kawakami; Andrew Ruszkiewicz; Graeme Bennett; James Moore; Barry Iacopetta
Journal:  Mol Cancer       Date:  2006-01-10       Impact factor: 27.401

View more
  9 in total

1.  Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population.

Authors:  Kensuke Kumamoto; Hideyuki Ishida; Okihide Suzuki; Yusuke Tajima; Noriyasu Chika; Koki Kuwabara; Keiichiro Ishibashi; Katsuharu Saito; Koji Nagata; Hidetaka Eguchi; Junichi Tamaru; Takeo Iwama
Journal:  Surg Today       Date:  2015-08-07       Impact factor: 2.549

2.  Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.

Authors:  Masood Alqahtani; Caitlin Edwards; Natasha Buzzacott; Karen Carpenter; Khalid Alsaleh; Abdulmalik Alsheikh; Waleed Abozeed; Miral Mashhour; Afnan Almousa; Yousef Housawi; Shareefa Al Hawwaj; Barry Iacopetta
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

3.  Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases.

Authors:  Elisabeth F P Peterse; Steffie K Naber; Corinne Daly; Aaron Pollett; Lawrence F Paszat; Manon C W Spaander; Melyssa Aronson; Robert Gryfe; Linda Rabeneck; Iris Lansdorp-Vogelaar; Nancy N Baxter
Journal:  Clin Gastroenterol Hepatol       Date:  2019-10-17       Impact factor: 11.382

4.  Cancer Health Assessments Reaching Many (CHARM): A clinical trial assessing a multimodal cancer genetics services delivery program and its impact on diverse populations.

Authors:  Kathleen F Mittendorf; Tia L Kauffman; Laura M Amendola; Katherine P Anderson; Barbara B Biesecker; Michael O Dorschner; Devan M Duenas; Donna J Eubanks; Heather Spencer Feigelson; Marian J Gilmore; Jessica Ezzell Hunter; Galen Joseph; Stephanie A Kraft; Sandra Soo Jin Lee; Michael C Leo; Elizabeth G Liles; Nangel M Lindberg; Kristin R Muessig; Sonia Okuyama; Kathryn M Porter; Leslie S Riddle; Bradley A Rolf; Alan F Rope; Jamilyn M Zepp; Gail P Jarvik; Benjamin S Wilfond; Katrina A B Goddard
Journal:  Contemp Clin Trials       Date:  2021-05-11       Impact factor: 2.261

Review 5.  Deficient mismatch repair: Read all about it (Review).

Authors:  Susan Richman
Journal:  Int J Oncol       Date:  2015-08-12       Impact factor: 5.650

6.  Microsatellite instability use in mismatch repair gene sequence variant classification.

Authors:  Bryony A Thompson; Amanda B Spurdle
Journal:  Genes (Basel)       Date:  2015-03-30       Impact factor: 4.096

Review 7.  Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome).

Authors:  Daniel D Buchanan; Christophe Rosty; Mark Clendenning; Amanda B Spurdle; Aung Ko Win
Journal:  Appl Clin Genet       Date:  2014-10-06

8.  Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.

Authors:  Jenny von Salomé; Tao Liu; Markku Keihäs; Moni Morak; Elke Holinski-Feder; Ian R Berry; Jukka S Moilanen; Stéphanie Baert-Desurmont; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

9.  Efficient and reproducible identification of mismatch repair deficient colon cancer: validation of the MMR index and comparison with other predictive models.

Authors:  Patrick Joost; Pär-Ola Bendahl; Britta Halvarsson; Eva Rambech; Mef Nilbert
Journal:  BMC Clin Pathol       Date:  2013-12-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.